Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: A meta-analysis of randomized controlled trials

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Shen, Longxiang ^a   Xie, Xuetao ^a   Su, Yan ^a   Luo, Congfeng ^a   Zhang, Changqing ^a   Zeng, Bingfang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; PARATHYROID HORMONE; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ARTICLE; BONE DENSITY; CONTROLLED STUDY; DISTAL RADIUS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FEMUR NECK; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; RADIUS; RANDOMIZED CONTROLLED TRIAL; TISSUE DISTRIBUTION; TREATMENT DURATION; BONE; COMPARATIVE STUDY; DRUG EFFECT; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; MALE; OSTEOPOROSIS; PARATHYROID HORMONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80054002136     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026267     Document Type: Article

References (38)

1. (1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94: 646-650.
2. Cremers SC, Pillai G, Papapoulos SE, (2005) Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 44: 551-570.
3. Mulder JE, Kolatkar NS, LeBoff MS, (2006) Drug insight: Existing and emerging therapies for osteoporosis. Nat Clin Pract Endocrinol Metab 2: 670-680.
4. Macedo JM, Macedo CR, Elkis H, De Oliveira IR, (1998) Meta-analysis about efficacy of anti-resorptive drugs in post-menopausal osteoporosis. J Clin Pharm Ther 23: 345-352.
5. Miller PD, (2005) Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Clin Ther 27: 361-376.
6. Reszka AA, Rodan GA, (2003) Mechanism of action of bisphosphonates. Curr Osteoporos Rep 1: 45-52.
7. Heaney RP, Yates AJ, Santora AC, (1997) Bisphosphonate effects and the bone remodeling transient. J Bone Miner Res 12: 1143-1151.
8. Boonen S, Vanderschueren D, Venken K, Milisen K, Delforge M, et al. (2008) Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance. J Intern Med 264: 315-332.
9. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, et al. (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434-1441.
10. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, et al. (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349: 1207-1215.
11. Jodar-Gimeno E, (2007) Full length parathyroid hormone (1-84) in the treatment of osteoporosis in postmenopausal women. Clin Interv Aging 2: 163-174.
12. Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, et al. (2003) Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88: 5212-5220.
13. Adami S, Brandi ML, Canonico PL, Minisola G, Minisola S, et al. (2010) Appropriate use of anabolic treatment for severe osteoporosis. Clin Cases Miner Bone Metab 7: 114-122.
14. Moricke R, Rettig K, Bethke TD, (2011) Use of recombinant human parathyroid hormone(1-84) in patients with postmenopausal osteoporosis: a prospective, open-label, single-arm, multicentre, observational cohort study of the effects of treatment on quality of life and pain-the PROPOSE study. Clin Drug Investig 31: 87-99.
15. Lyritis GP, Georgoulas T, Zafeiris CP, (2010) Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis. Ann N Y Acad Sci 1205: 277-283.
16. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, et al. (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20: 1185-1194.
17. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, et al. (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182: 1864-1873.
18. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6: e1000100.
19. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12.
20. Finkelstein JS, Wyland JJ, Lee H, Neer RM, (2010) Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 95: 1838-1845.
21. Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis GN, et al. (2008) Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial. Int J Clin Pract 62: 919-924.
22. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, et al. (2005) Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165: 1762-1768.
23. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, et al. (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349: 1216-1226.
24. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, et al. (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87: 4528-4535.
25. Cosman F, Eriksen EF, Recknor C, Miller PD, Guanabens N, et al. (2011) Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 26: 503-511.
26. Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, et al. (2005) Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353: 566-575.
27. Saag KG, Shane E, Boonen S, Marin F, Donley DW, et al. (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357: 2028-2039.
28. Nevitt MC, Chen P, Dore RK, Reginster JY, Kiel DP, et al. (2006) Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int 17: 273-280.
29. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, et al. (2003) The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18: 9-17.
30. Vestergaard P, Jorgensen NR, Mosekilde L, Schwarz P, (2007) Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk-a meta-analysis. Osteoporos Int 18: 45-57.
31. Schneider PF, Fischer M, Allolio B, Felsenberg D, Schroder U, et al. (1999) Alendronate increases bone density and bone strength at the distal radius in postmenopausal women. J Bone Miner Res 14: 1387-1393.
32. Hirano T, Burr DB, Turner CH, Sato M, Cain RL, et al. (1999) Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J Bone Miner Res 14: 536-545.
33. Mashiba T, Burr DB, Turner CH, Sato M, Cain RL, et al. (2001) Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits. Bone 28: 538-547.
34. Borba VZ, Manas NC, (2010) The use of PTH in the treatment of osteoporosis. Arq Bras Endocrinol Metabol 54: 213-219.
35. Verhaar HJ, Lems WF, (2009) PTH-analogs: comparable or different? Arch Gerontol Geriatr 49: e130-132.
36. Vahle JL, Sato M, Long GG, Young JK, Francis PC, et al. (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30: 312-321.
37. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, et al. (2005) One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353: 555-565.
38. Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, et al. (2000) Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85: 2129-2134.